PDS Biotechnology (PDSB) Amortizatization of Intangibles (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Amortizatization of Intangibles came in at $474408.0 in Q4 2025, down 57.94% YoY from $1.1 million in Q4 2024, and up 476.23% on a QoQ basis from $82329.0 in Q2 2025.
PDS Biotechnology (PDSB) Amortizatization of Intangibles (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 9 years of Amortizatization of Intangibles data on file, last reported at $474408.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles fell 57.94% year-over-year to $474408.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $566407.0 (down 67.19% YoY) and the FY2025 annual result came in at $1.6 million, up 34.31% from the prior year.
- Amortizatization of Intangibles improved to $474408.0 in Q4 2025, from $82329.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.1 million in Q4 2024 to a low of -$351953.0 in Q4 2023.
- A 4-year average of $185860.2 and a median of $111192.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles tumbled 416.53% — and 2024, when it soared 420.47%.
- Tracing PDSB's Amortizatization of Intangibles over 4 years: stood at $111192.0 in 2022, then plunged by 416.53% to -$351953.0 in 2023, then soared by 420.47% to $1.1 million in 2024, then sank by 57.94% to $474408.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $474408.0 (Q4 2025), $82329.0 (Q2 2025), and $9670.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 265,549.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 265,549.00 |
| Jun 30, 2026 | 265,549.00 |
| Dec 31, 2025 | 474,408.00 |
| Dec 31, 2025 | 474,408.00 |
| Jun 30, 2025 | 82,329.00 |
| Jun 30, 2025 | 82,329.00 |
| Mar 31, 2025 | 9,670.00 |
| Mar 31, 2025 | 9,670.00 |
| Dec 31, 2024 | 1.13 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 305,125.00 |
| Sep 30, 2024 | 305,125.00 |
| Jun 30, 2024 | 283,774.00 |
| Jun 30, 2024 | 283,774.00 |
| Mar 31, 2024 | 9,670.00 |
| Mar 31, 2024 | 9,670.00 |
| Dec 31, 2023 | -351,953.00 |
| Dec 31, 2023 | -351,953.00 |
| Sep 30, 2023 | 158,397.00 |
| Sep 30, 2023 | 158,397.00 |